ATLANTA, GA--(Marketwire - December 18, 2007) - AtheroGenics, Inc. (NASDAQ: AGIX) today announced that the Company has completed enrollment of its double-blind, placebo controlled Phase III ANDES clinical trial of AGI-1067, a novel oral anti-inflammatory antioxidant agent in development for the treatment of type 2 diabetes.
